Tag Archives: Avastin

What Does ‘Off Label’ Mean in 2014?

by Tom Norton Years ago, while sitting in an Rx company lunch room, I was listening to one of the company’s top sales reps discuss the commercial progress a recently launched prescription was making. The rep said that the product was selling “OK” under its FDA approved, indicated therapeutic area. However, he quietly said, “It’s […]
Posted in Biotech, FDA, Guest Blog, healthcare, Legal, Market Access, Marketing, pricing, Regulatory, Strategy | Also tagged , | 1 Comment

Pharm Exec's Brands of Yesteryear: Where Are They Now?

Pharm Exec’s Brand of the Year selections from the last few years are still alive and kicking, although some have aged more gracefully than others. The US drug pricing wars may be coming, but these products already made their mint. We checked back in with them to see how things are going, and to look […]
Posted in Pharm Exec Magazine, R&D, Strategy | Also tagged , , , , , | Leave a comment

In the Absence of Avastin: New Opportunity

written by guest blogger Ed Kissel, Vice President of Quantitative Analysis In July 2010, an advisory panel voted 12-1 to urge the FDA to withdraw the approved use of Avastin in metastatic HER2-negative breast cancer. As a result of this announcement, IntrinsiQ hypothesized that physicians would immediately decrease the use the drug in new patients. […]
Posted in Strategy | Also tagged | Leave a comment

Advisory Panel Rejects Avastin For Breast Cancer Treatment

An FDA advisory panel on Tuesday voted 12–1 to discontinue Avastin (bevacizumab) as a treatment for advanced breast cancer due to post-market studies stating that the treatment does not to increase patient lifespan by any significant length of time. This is a huge problem for Roche who purchased the treatment as part of its merger […]
Posted in FDA, Safety | Also tagged , , , , , , , | 1 Comment

Avastin Gets Green Light for Use in Kidney Cancer

Image by Getty Images via Daylife Score another win for Genentech and its cancer treatment Avastin (bevacizumab). On Monday, the biotech giant, now owned entirely by Roche, announced that FDA has approved the drug for kidney cancer. Avastin blocks new blood vessels from forming and supplying tumors with the nutrients they need to grow and […]
Posted in News | Also tagged , , , , , , | Leave a comment
  • Categories

  • Meta